Contact

Research

Scientific Abstracts/
Presentations
0
Peer Reviewed
Publications
0
Patients
Studied
0 +

Outcomes from AeroPace Clinical Studies Showed

Using AeroPace compared to Standard of Care, more patients weaned.

Up to 35% reduced risk of remaining on MV at day 30
0 %
Up to 46% fewer reintubations and tracheostomies
0 %
Fewer days on MV
in the ICU
3

Published Research

Linkedin Twitter Youtube

© 2024 Lungpacer Medical Inc. ®

_

AEROPACE SYSTEM INDICATIONS FOR USE

The AeroPace System is indicated to improve weaning success – increase weaning, reduce ventilator days, and reduce reintubation – in patients ages 18 years or older on mechanical ventilation ≥ 96 hours and who have not weaned.

SAFETY INFORMATION

Do not use the AeroPace System with active implanted cardiac pacemakers, defibrillators, or other implantable electronics within proximity to the AeroPace Neurostimulation Catheter. The AeroPace System has not been clinically evaluated for safety with these implantable electronic devices.

Risks include those that may occur with the use of central venous catheters and the risks of nerve and diaphragm stimulation.  These may include the risks of infection, blood vessel damage, or cardiac effects that can occur with use of catheters.  Stimulation risks are rare and may include nerve injury or fatigue of the breathing muscle.

_

CAUTION: The AeroNova System is limited by Federal law (United States) to investigational use. Used exclusively for clinical investigations.

_

Lungpacer® Medical, AeroPace® System and AeroNova® System are registered trademarks of Lungpacer Medical.